Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

A consensus regarding standard adjuvant chemotherapy for curatively resected gastric cancer has not been obtained between Japan and the Western world. In order to evaluate the effect of a tegafur-based regimen (the most frequently used regimen in Japan) compared with a surgery-alone control, a meta-analysis was performed, investigating four clinical trials. After meticulous examination of each trial, trials with improper noncentralized randomization were excluded from the analysis. A total of 1197 patients were enrolled in the four relevant trials determined to be eligible for the meta-analysis (Nakajima 1984; Japan Clinical Oncology Group [JCOG] 8801, JCOG 9206-2, and National Surgical Adjuvant Study of Gastric Cancer [NSASGC], in which a tegafur-based regimen was used for chemotherapy and central randomization was performed. The endpoint was overall survival, and a common hazard ratio was estimated. The 5-year overall survival rates differed among the trials because of differences in the background disease status. But there was no heterogeneity (P = 0.235) of treatment effect. The estimated common hazard ratio was 0.75, with a 95% confidence interval of 0.58–0.98. The treatment effect of the tegafur-based agent was shown to be statistically significant (P = 0.037) compared with surgery-alone therapy (n = 1179). From the results of the above meta-analysis, it is suggested that chemotherapy with a tegafur-based agent after surgery can improve the survival of patients with curatively resected gastric cancer. The Global Advanced/Adjuvant Stomach Tumor Research through International Collaboration (GASTRIC) group is conducting two individual patient data meta-analyses, testing post-operative adjuvant chemotherapy for resect-able gastric cancer and chemotherapy for advanced gastric cancer. It is expected to determine and quantify the role of adjuvant chemotherapy in detail from the GASTRIC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002 (2004) Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. IARC, Lyon

    Google Scholar 

  2. Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:204–213

    PubMed  CAS  Google Scholar 

  3. Macdonald JS, Smalley SR, Benedetti J, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730

    Article  PubMed  CAS  Google Scholar 

  4. Macdonald JS (2004) Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 54:S4–S11

    PubMed  CAS  Google Scholar 

  5. Maehara Y, Baba H, Sugimachi K (2001) Adjuvant chemotherapy for gastric cancer: a comprehensive review. Gastric Cancer 4:175–184

    Article  PubMed  CAS  Google Scholar 

  6. Saka M, Sasako M, Katai H, et al. (2000) Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer (in Japanese). Jpn J Cancer Chemother 27:2033–2042

    CAS  Google Scholar 

  7. Sasaki T (2004) In regard to gastric cancer treatment guidelines — a revised edition (in Japanese). Jpn J Cancer Chemother 21:1947–1951

    Google Scholar 

  8. Oba K, Morita S, Tsuburaya A, et al. (2006) Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 18:311–317

    PubMed  CAS  Google Scholar 

  9. Sakamoto J, Morita S, Kodera Y, et al. (2004) Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 54:S25–S31

    Article  PubMed  CAS  Google Scholar 

  10. Ohta K (2000) Present status of treatment for stomach cancer in Japan (from the questionnaire) (in Japanese). J Ther 82:1782–1783

    Google Scholar 

  11. Parmar MB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  PubMed  CAS  Google Scholar 

  12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  13. Nakajima T, Takahashi T, Takagi K, et al. (1984) Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 2:1366–1371

    PubMed  CAS  Google Scholar 

  14. Honda I, Watanabe S, Fujita Y (1997) Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer (in Japanese). Jpn J Cancer Chemother 24:1109–1117

    CAS  Google Scholar 

  15. Tsugita M, Takasaki K, Yagawa A, et al. (1992) An evaluation of perioperative and continuous infusion of tegafur as surgical adjuvant chemotherapy of resected gastric cancer (in Japanese). Jpn J Cancer Chemother 19:333–337

    CAS  Google Scholar 

  16. Nakajima T, Nashimoto A, Kitamura M, et al. (1999) Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Gastric Cancer Surgical Study Group. Lancet 354:273–277

    Article  PubMed  CAS  Google Scholar 

  17. Yoshino H, Fujita M, Hirata K, et al. (2000) Interim report on JFMTC Study no.21 on effectiveness of UFT as an adjuvant therapy for semi-advanced cancer of the stomach (in Japanese). Jpn J Cancer Chemother 27:263–270

    CAS  Google Scholar 

  18. Miyashiro I, Furukawa H, Sasako M, et al. (2005) No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer: Japan Clinical Oncology Group 9206-2. 2005 Gastrointestinal Cancers Symposium Proceedings Miami, Jan 27–29: abstract no.4

  19. Kinoshita T, Nakajima T, Ohashi Y, et al. (2005) Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: results of a randomized trial by National Surgical Adjuvant Study Of Gastric Cancer. Proc Am Soc Clin Oncol 23:313s

    Google Scholar 

  20. Sakuramoto S, Sasako M, Yamaguchi T, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

    Article  PubMed  CAS  Google Scholar 

  21. Di Costanzo F, Gasperoni S, Manzione L, et al. (2008) Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100:388–398

    Article  PubMed  Google Scholar 

  22. Kattan MW, Karpeh MS, Mazumdar M, et al. (2003) Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21:3647–3650

    Article  PubMed  Google Scholar 

  23. Kikuchi S, Sakakibara Y, Sakuramoto S, et al. (2001) Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. Anticancer Res 21:3589–3593

    PubMed  CAS  Google Scholar 

  24. Sakamoto J, Paoletti X, on behalf of the Global Adv/Adj Stomach Tumor Research through International Collaboration (GASTRIC). (2008) Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy in gastric cancer. Proc Am Soc Clin Oncol 26:4543s

    Google Scholar 

  25. Rougier P, Oba K, on behalf of the Global Adv/Adj Stomach Tumor Research through International Collaboration (GASTRIC). (2008) Meta-analyses of randomized trials assessing the interest chemotherapy in advanced gastric cancer. Proc Am Soc Clin Oncol 26:4563s

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. EBM Research Center, Kyoto University Graduate School of Medicine, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan

    Koji Oba

Authors
  1. Koji Oba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Oba.

About this article

Cite this article

Oba, K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol 14, 85–89 (2009). https://doi.org/10.1007/s10147-009-0877-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-009-0877-4

Key words

Search

Navigation